| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2a97323dcd3bad3f6e128b046f5273a |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2013-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91b86b5d5a27779ca3a8f72991fdbb29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be00f6d7bfa6261387db0da09ee13165 |
| publicationDate |
2014-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014162739-A |
| titleOfInvention |
Bispecific antibodies and pharmaceutical compositions |
| abstract |
A novel bispecific antibody having sufficient target binding properties is provided. It has a first specificity for EphA10 and a second specificity for a surface antigen expressed in cells having cytotoxic activity. Cells having cytotoxic activity are cytotoxic T cells. The antigen expressed on cytotoxic T cells is CD3. The structure of the bispecific antibody is tandem. [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023088482-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11142574-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017536111-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017538441-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023088483-A1 |
| priorityDate |
2013-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |